Trial Period: ACT intervention data in Antenatal Corticosteroids Trial in Preterm Births to Increase Neonatal Survival in Developing Countries

Maternal characteristics among women in the ACT treatment group who were identified as high risk for preterm birth as collected by the ACT study team on Form ACT01 during the ACT Trial
Study Description
ACT, funded by the NICHD, studied the feasibility, effectiveness and safety of a multifaceted intervention designed to increase the use of antenatal corticosteroids (ACS) at all levels of health care in low- and middle-income countries. Investigators conducted a two-arm parallel cluster randomized trial of women enrolled in the Global Network Maternal Newborn Health Registry. Intervention clusters received health-provider training, posters, pregnancy disc, and uterine height tape to facilitate identification of women at risk of preterm birth, and ACS kits. All health providers in intervention clusters were trained to identify women presenting before 36 weeks’ gestation with signs of labor, PPROM, pre-eclampsia/eclampsia, or obstetric hemorrhage as at high risk of preterm birth and potential candidates for ACS. The primary outcome was 28-day neonatal mortality among infants less than the 5th percentile for birth weight (a proxy for preterm birth). In the 50 intervention clusters 46,172 pregnant women, 45,369 live births(LB) and 1,266 stillbirths(SB) and in the 50 control clusters 51,523 pregnant women, 50,743 LB and 1,264 SB were enrolled, completed follow-up and are included in this data release.